In the case of T2D, IL-6 inhibition may have potential antidiabetic properties because IL-6 is known to contribute to IR by inducing the overexpression of SOCS-3 (suppressor of cytokine signaling 3), a possible inhibitor of insulin signaling. Here, IL6 is linked to type 2 diabetes mellitus.